GlobeNewswire Inc | Dec 15, 2020 08:00AM EST

December 15, 2020

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI).The addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).The NASDAQ Biotechnology Index is re-ranked annually.All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

The NASDAQ Biotechnology Index forms the basis for a number of Exchange Traded Funds (ETFs), including theiShares NASDAQ Biotechnology ETF(Nasdaq: IBB).More information about the Index can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.

AboutApplied TherapeuticsApplied Therapeuticsis a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companys lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial inJune 2019, read out positive top-line biomarker data in adult Galactosemia patients inJanuary 2020and announced full data from the trial inApril 2020. A pediatric Galactosemia study commenced inJune 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM inSeptember 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications. To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Investors:Maeve Conneighton(212) 600-1902 orappliedtherapeutics@argotpartners.com

Media:Gleb Sagitovmedia@appliedtherapeutics.com